Previous 10 | Next 10 |
Shares of Eton Pharmaceuticals are down 10% in after-hours trading after the company said that Azurity Pharmaceuticals received a Complete Response Letter from the U.S. FDA for its lamotrigine product candidate. Although Eton (NASDAQ:ETON) sold its neurology portfolio to Azurit...
Gainers: Fanhua (FANH) +7%. Ocular Therapeutix (OCUL) +5%. ThredUp (TDUP) +5%. Cara Therapeutics (CARA) +3%. LegalZoom.com (LZ) +3%. Losers: Eton Pharmaceuticals (ETON) -21%. Allakos (ALLK) -7%. Accolade (ACCD) -5%. Sono Group (SEV) -5%. FTC Solar (FTCI) -4%. For furth...
Eton Pharmaceuticals, Inc. (ETON) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants David Krempa – Senior Vice President-Business Development and Investor Relations Sean Brynjelsen – Chief Executive Officer James Gruber – Chief Financial Office...
Eton Pharmaceuticals press release (NASDAQ:ETON): Q1 GAAP EPS of -$0.21. Revenue of $2.18M. For further details see: Eton Pharmaceuticals GAAP EPS of -$0.21, revenue of $2.18M
DEER PARK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the first quarter ended March 31, 2022. “W...
DEER PARK, Ill., May 03, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2022 financial results on Thursday, May ...
James Gruber has been appointed as the new CFO of Eton Pharmaceuticals (NASDAQ:ETON), succeeding Wilson Troutman, who is retiring. Troutman has agreed to remain with the company through the end of May to facilitate the transition. Gruber has over 20 years of financial and accounting experienc...
DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of James Gruber as Chief Financial Officer, effective im...
Veru (VERU) +31% after interim results for COVID-19 therapy. SailPoint Technologies (SAIL) +30% acquisition could lead to other cyber security deals, Wedbush says. Iveda Solutions (IVDA) +28%. VNET Group (VNET) +20% receives buyout offer of $1.3333 per share. Aff...
Eton Pharmaceuticals (NASDAQ:ETON) has added ~12% in the pre-market on Monday after the Deer Park, Illinois-based company announced that the U.S. Food and Drug Administration (FDA) issued final approval for its cysteine hydrochloride abbreviated new drug application (ANDA). The prod...
News, Short Squeeze, Breakout and More Instantly...
Eton Pharmaceutcials Inc. Company Name:
ETON Stock Symbol:
NASDAQ Market:
Eton Pharmaceutcials Inc. Website:
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innov...
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13 th straight quarter of sequential product sales growth • Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...